View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 27, 2015

Boehringer and Eli Lilly receive FDA approval for Synjardy to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals and Eli Lilly have received approval from the US Food and Drug Administration (FDA) for Synjardy (empagliflozin and metformin hydrochloride) tablets to treat type 2 diabetes (T2D).

Boehringer Ingelheim Pharmaceuticals and Eli Lilly have received approval from the US Food and Drug Administration (FDA) for Synjardy (empagliflozin and metformin hydrochloride) tablets to treat type 2 diabetes (T2D).

According to Boehringer, Synjardy is the third product containing empagliflozin to have received FDA approval, after Jardiance (empagliflozin) and Glyxambi (empagliflozin / linagliptin).

Empagliflozin is a sodium glucose co-transporter-2 (SGLT2) inhibitor, which removes excess glucose through the urine by blocking glucose re-absorption in the kidney.

"Our alliance is proud to offer a diverse portfolio of treatments that can help patients throughout their diabetes journey."

Synjardy is a combination of two medicines, including empagliflozin and metformin, with complementary mechanisms of action that will control blood glucose in people with T2D.

The tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with empagliflozin and metformin.

Boehringer Ingelheim Pharmaceuticals president and CEO Paul Fonteyne said: "Synjardy is now the fifth FDA-approved medicine to emerge from the BI-Lilly Diabetes alliance pipeline in the last four years.

"No two people with diabetes are alike, and every experience is different. Our alliance is proud to offer a diverse portfolio of treatments that can help patients throughout their diabetes journey."

Metformin is an initial treatment for T2D, which reduces glucose production by the liver and its absorption in the intestine.

In 2011, Boehringer Ingelheim and Eli Lilly established partnership in diabetes to focus on compounds representing several of the largest diabetes treatment classes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU